E-Mail
IMAGE: Dr. Catherine Van Poznak is the co-chair of a new SWOG Cancer Research Network trial that details, for the first time, the incidence of a common bone disease in cancer. view more
Credit: University of Michigan Rogel Cancer Center
PORTLAND, OR - A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.
Dec 17, 2020
The annual meeting of the San Antonio Breast Cancer Symposium was held virtually this year from Dec. 8 to 11 and attracted participants from around the world, including medical oncologists, radiation oncologists, researchers, and other health care professionals. The conference highlighted recent advances in the risk, diagnosis, treatment, and prevention of breast cancer, with presentations focusing on emerging treatments in hard-to-treat patient populations, including patients with metastatic breast cancer.
As part of the RxPONDER study, Kevin Kalinsky, M.D., of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University in Atlanta, and colleagues found that postmenopausal women with lymph node-positive early-stage breast cancer and a low recurrence score receive no additional benefit from chemotherapy.
COVID-19 is the big story in mortality statistics - but not the only one chron.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chron.com Daily Mail and Mail on Sunday newspapers.
Ignored, Erased, Unheard: The Doctor Behind the Name Change of Bard Hall
Ignored, Erased, Unheard: The Doctor Behind the Name Change of Bard Hall Natalie Tak / Staff Illustrator December 15, 2020, 9:57 PM
Halfway through the interview with Dr. Raymond Givens, two young boys materialize through the slightly-pixelated Zoom virtual background displaying the stoic face of the rapper Biggie Smalls. The little one pops cheerfully through the famous rapper’s mouth, waving a tiny green toy at the camera, and the taller one comes running through the rapper’s tilted plastic crown, grinning cheekily and tugging at his father’s surgical scrubs. Givens, smiling at his sons and not at all fazed by the distraction, smoothly introduces his six-year-old, Lucas, and his two-year-old, Nicholas, pausing momentarily to swoop Nicholas into his lap and put his arm around Lucas’ shoulder. Givens gently corrals them out of the room, apologizes for the interruption, and without missing a beat,
email article
The idea that old vaccines might have a role in the fight against COVID-19 has been floated since the early days of the pandemic. Vaccines stimulate the broad, innate immune response, which appears to play a key role in fighting COVID-19. Can the approach bridge the time until entire populations are vaccinated specifically against SARS-CoV-2?
Three vaccines dominate the discussion: bacillus Calmette-Guérin (BCG) against tuberculosis; measles, mumps, and rubella (MMR); and oral polio vaccine (OPV).
BCG has been associated with milder courses of infection for respiratory syncytial virus, human papillomavirus, herpes simplex, and influenza. Fifteen clinical trials are testing it for COVID-19, but a drawback is the 1% rate of adverse events.